<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Medill Reports Chicago</provider_name><provider_url>https://news.medill.northwestern.edu/chicago</provider_url><title>Drug price reform, biosimilars threaten AbbVie - Medill Reports Chicago</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="bQqzCjwYNU"&gt;&lt;a href="https://news.medill.northwestern.edu/chicago/drug-price-reform-biosimilars-threaten-abbvie/"&gt;Drug price reform, biosimilars threaten AbbVie&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://news.medill.northwestern.edu/chicago/drug-price-reform-biosimilars-threaten-abbvie/embed/#?secret=bQqzCjwYNU" width="600" height="338" title="&#x201C;Drug price reform, biosimilars threaten AbbVie&#x201D; &#x2014; Medill Reports Chicago" data-secret="bQqzCjwYNU" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script&gt;
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://news.medill.northwestern.edu/chicago/wp-includes/js/wp-embed.min.js
&lt;/script&gt;
</html><thumbnail_url>https://news.medill.northwestern.edu/chicago/wp-content/uploads/sites/3/2017/02/cvs-pharmacy1.jpg</thumbnail_url><thumbnail_width>1100</thumbnail_width><thumbnail_height>825</thumbnail_height><description>By Rachel Newman North Chicago, Ill.-based pharmaceutical company AbbVie, Inc. is feeling the heat as drug pricing reform and competitive pressures threaten to undercut the sales of its blockbuster drug Humira. Sales of Humira, an immunosuppressant used to treat autoimmune disorders such as psoriasis and Crohn&#x2019;s disease, accounted for nearly 63 percent of the company&#x2019;s [&hellip;]</description></oembed>
